title: Advantages and safety of local treatment with MMC/Beriplast P for cancer tumors.
abstract: To target the treatment of small points of cancer, Beriplast P, already used clinically as a physiological tissue adherent drug carrier, was mixed with the anticancer drug, mitomycin C (MMC). In this in vitro study, MMC did not release quickly from the clot of MMC/Beriplast P. The antitumor effect of this mixture was examined for its effect on cancer growth. In one series of experiments, tumor tissues were inoculated with MMC/100 microliters Beriplast P and in another series, MMC/100 microliters Beriplast P was injected into tumors at a weight of 300 mg. In the first series of experiments, tumor tissue treated with 0.3 mg MMC/100 microliters Beriplast P was replaced with plasma cells and lymphocytes, and no viable cancer cells could be found. In the second series, MMC/100 microliters Beriplast P delayed tumor growth, and the survival of Balb/c mice injected with 0.08 mg MMC/100 microliters Beriplast P was significantly longer than that of mice injected with 0.08 mg MMC/100 microliters saline solution (P = 0.026). In addition, the abdominal aorta, vena cava, and intestine around the area of treatment with 1.6 mg MMC/100 microliters Beriplast P were not damaged. These results indicate that the mixture of Beriplast P and MMC is more effective than MMC solution alone in the local treatment of residual cancer.
authors.affiliation: Clinical Research Institute, National Kyushu Cancer Center, Fukuoka, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Matsuoka
authors.forename: K
authors.initials: K
authors.lastname: Yano
authors.forename: Y
authors.initials: Y
authors.lastname: Katsuta
authors.forename: M
authors.initials: M
authors.lastname: Morita
authors.forename: S
authors.initials: S
authors.lastname: Kounoe
authors.forename: Y
authors.initials: Y
authors.lastname: Seo
authors.forename: T
authors.initials: T
authors.lastname: Saito
authors.forename: H
authors.initials: H
authors.lastname: Tomoda
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001011:Aorta / Q000187:drug effects / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D015718:Fibrin Tissue Adhesive / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D007410:Intestinal Diseases / Q000139:chemically induced; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D016685:Mitomycin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D009368:Neoplasm Transplantation; D051381:Rats; D011916:Rats, Inbred F344; D012513:Sarcoma, Experimental / Q000188:drug therapy* / Q000473:pathology; D000267:Tissue Adhesions / Q000139:chemically induced; D014407:Tumor Cells, Cultured; D014684:Venae Cavae / Q000187:drug effects / Q000473:pathology
chemical_list: D000903:Antibiotics, Antineoplastic; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D015718:Fibrin Tissue Adhesive; D016685:Mitomycin